Research programme: infectious disease vaccines - Affinivax

Drug Profile

Research programme: infectious disease vaccines - Affinivax

Latest Information Update: 03 Mar 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Affinivax
  • Class Bacterial vaccines; Conjugate-vaccines; Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bacterial infections; Pneumococcal infections
  • Research Nosocomial infections

Most Recent Events

  • 28 Feb 2017 Pneumococcal vaccines licensed to Astellas Pharma worldwide for the treatment of Pneumococcal infections
  • 05 Feb 2016 Affinivax announces intention to submit IND to US FDA for Pneumococcal vaccine
  • 26 Oct 2015 Affinivax and Nosocomial Vaccine Corporation agree to co-develop Bacterial vaccines in USA for Nosocomial infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top